Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

hma later this month."

2013 Business Highlights EYLEA® (aflibercept) Injection for Intravitreal Injection

  • EYLEA is currently approved in the United States for the treatment of neovascular age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion (CRVO).  In the first quarter of 2013, net sales were $314 million, compared to $124 million in the first quarter of 2012, and $276 million in the fourth quarter of 2012.
  • The Company and Bayer HealthCare collaborate on the global development and commercialization of EYLEA outside the United States, and share profits and losses from commercialization of EYLEA outside the United States except for Japan, where the Company receives a royalty on sales.  Regeneron maintains exclusive rights to EYLEA in the United States and is entitled to all profits from any such sales.
  • Bayer HealthCare commenced sales of EYLEA for the treatment of wet AMD in the fourth quarter of 2012 following receipt of regulatory approvals in the European Union, Japan, Australia, and other regions.  In the first quarter of 2013, Bayer HealthCare recorded net sales of EYLEA outside of the United States of $65 million, compared to $19 million in the fourth quarter of 2012.  Our share of profits (including royalties on sales in Japan) for EYLEA was $19 million, and after repaying $13 million in development expenses, we recognized $6 million in net profit from EYLEA sales outside the United States in the quarter.
  • Launches in additional countries are anticipated to continue throughout 2013 as regulatory and pricing approvals for EYLEA for the treatment of wet AMD are achieved.
  • Applications for marketing authorization for EYLEA for the treatment of macular edema following CRVO are also pending in Europe, Japan, and other regions.
  • Regeneron and Bayer HealthCare are conducting Phase 3 trials, VISTA-DME and VIVID-DME,
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
    2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
    3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
    4. Regeneron Announces March 2012 Investor Conference Presentations
    5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
    8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
    9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
    10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
    11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... published today (August 22nd), in the scientific journal ... Neuroscience Programme establish the effect of serotonin on ... genetic and optical techniques., "Serotonin is a small ... range of brain functions, from the control of ... emotional behaviours, This neurotransmitter is also popularly thought ...
    (Date:8/22/2014)... 22, 2014 Research and Markets ... China Gel Permeation Chromatography (GPC) Industry Report 2014" ... and China Gel Permeation Chromatography (GPC) Industry Report is ... of the global gel permeation chromatography industry with a ... a basic overview of the industry including definitions, classifications, ...
    (Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
    (Date:8/21/2014)... 2014 2014 Deep Research ... a professional and in-depth research report on ... basic Seaweed Fertilizer information, including Seaweed Fertilizer ... as well as industry overview. This research ... market as well as global industry analysis ...
    Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
    ... Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial results for ... For the quarter ended December 31, 2007, the Company reported ... compares to a net loss of,$68.1 million, or $1.18 per ... $0.58 per share, for the prior quarter ended September 30,2007. ...
    ... MANASQUAN, N.J., Feb. 26 BioSpace, the world,s ... career fair company,welcomed over 900 biotechnology and pharmaceutical ... Massachusetts on February 19, 2008., Thirty-six bioscience ... thoroughly impressed with the quality as well as ...
    ... Microsoft Gold Certified Partner Provides Framework, for ... Solutions, ORLANDO, Fla., Feb. 26 ... software and services for health and,human services ... Certified Partner status in the Microsoft Partner ...
    Cached Biology Technology:CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8BioSpace Boston Career Fair Attracts over 900 Bioscience Candidates 2Netsmart Technologies Announces Development Program on Microsoft for Local Public Health Clinic Management and Vital Records Software 2Netsmart Technologies Announces Development Program on Microsoft for Local Public Health Clinic Management and Vital Records Software 3
    (Date:8/21/2014)... heard of the water window? It consists of radiations ... not absorbed by the water in biological tissues. New ... coherent radiations within the water window. These could be ... high-contrast image of the biological samples or to be ... identifies the physical mechanism needed to efficiently generate the ...
    (Date:8/21/2014)... RUSTON, La. A team of researchers ... innovative method for using affordable, consumer-grade 3D ... implants that can contain antibacterial and chemotherapeutic ... team comprised of doctoral students and research ... nanosystems engineering programs collaborated to create filament ...
    (Date:8/20/2014)... E. Fox, a John and Rebecca Moores Professor of Biology ... a fellow in the International Society for the Study of ... of four members two from the U.S., one from ... 2014. Fellows are elected every three years, and 36 have ... more than 20 countries, the ISSOL includes researchers from disciplines ...
    Breaking Biology News(10 mins):Water window imaging opportunity 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3UH professor named fellow by International Astrobiology Society 2
    ... (ESA) will present its fifth annual Regional Policy Award ... during the Society,s upcoming conference in Portland, Oregon. The ... who has an outstanding record of informing political decision-making ... present this prestigious award to Ken Bierly for his ...
    ... (Boston) A recent study led by Boston University School ... plays a significant role in the regulation of high fat, ... which are published online in PLoS ONE , also ... type 2 diabetes. Katya Ravid, DSc/PhD, professor of ...
    ... Institution (WHOI) researchers have partnered with two companies ... WHOI: the Imaging FlowCytobot, an automated underwater microscope, ... light to provide wireless transmission of data, including ... WHOI biologists Robert Olson and Heidi Sosik, creators ...
    Cached Biology News:Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 2Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 3BUSM study identifies receptor's role in regulating obesity, type 2 diabetes 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 3WHOI scientists/engineers partner with companies to market revolutionary new instruments 4
    ... is pleased to offer the ATTO-TAG ... detection of primary amines. Developed by ... the ATTO-TAG reagents are similar to ... (NDA) and anthracene-2,3-dicarboxaldehyde, all of which ...
    ...
    ...
    Human Cystatin A MAb (Clone 224705)...
    Biology Products: